Nutex Health Inc (NUTX)

[Vulcanized Crawler]

IGAMBIT Announces (((( MAY 8, 2017 ))))...
Dr. Benedict S Maniscalco joins its Advisory Board

SMITHTOWN, NY--(Marketwired - May 8, 2017) - iGambit Inc. (OTCQB: IGMB)
announced that Dr. Benedict S Maniscalco has joined its Senior Advisory
Board.

This follows the acquisition of HubCentrix and the CyberCare Health Network
Chronic Care Management System. Both companies operate as HealthDatix, Inc.

The goal of HealthDatix is to identify the patient's eligibility for
Medicare reimbursed doctor visits to access and assist in the well-being and
cultivation of a healthy lifestyle. Additionally HealthDatix will be able to
provide an FDA approved, Medicare covered platform, for continuous
management of chronic care patients. Our continuous care platform will be
tailored for individual care and health management of patients susceptible
to chronic illness. This will include CyberCare's wearable medical watch.

Dr. Benedict S. Maniscalco, M.D. received his medical degree from the Duke
University School of Medicine in 1967. He interned at Grady Memorial
Hospital in Atlanta and did his junior and senior residencies at Emory
University Affiliated Hospitals, followed by a fellowship in Cardiovascular
diseases from 1973-1975. He is licensed to practice in both Florida and
Georgia and is certified by the American Board of Internal Medicine and the
American Sub-Specialty Board in Cardiovascular disease.

From 1976 through early 1979 Dr. Maniscalco was on the faculty of the
University of South Florida School of Medicine, division of Cardiology in
Tampa, Florida. Later in 1979, Dr. Maniscalco was recruited to establish the
cardiac catheterization laboratory at St. Joseph's hospital in Tampa. He
subsequently expanded the program and founded the nationally recognized St.
Joseph's Heart Institute which served as a model for cardiovascular programs
throughout the country.

Dr. Maniscalco served as Chief of Cardiology and Director of the cardiac
catheterization laboratory until from its founding through 2001. In this
capacity, many of the innovative procedures and technology of modern
cardiovascular services were implemented.

While Director of the Heart Institute, Dr. Maniscalco was an officer and
director of a large multi-specialty cardiovascular group practice.

Over his distinguished career, Dr. Maniscalco has served as a consultant,
opinion leader and speaker for numerous companies in both the pharmaceutical
and device industry. He has lectured throughout the country for both medical
and industry colleagues. He has been involved and led many research efforts
in both clinical and non-clinical areas of investigation.

Dr. Maniscalco has been a member of and served many professional medical
societies. In the American College of Cardiology, he served in many
capacities at the local, state and national levels. He has made significant
contributions on numerous committees and in many capacities including his
tenure as President and Governor of the Florida Chapter of the American
College of Cardiology. His specific contributions in the areas of health
policy and socioeconomic issues were numerous.

Today, Dr. Maniscalco continues his devotion to patients in a consultative
and prevention cardiology practice in Tampa, Florida and on an international
basis as CEO and Chairman of Heartbeat International Foundation (HBI)! HBI
provides pacemakers, defibrillators and other cardiac services to the less
fortunate in developing countries of the world. Over 15,000 patients' lives
have been saved or changed by the efforts of Heartbeat International and the
many volunteer physicians and colleagues worldwide.

John Salerno, Chairman of iGambit: "We are very pleased to have Dr.
Maniscalco join us in our new business opportunity. His experience and
knowledge together with others that will be joining us will set a standard
by which we deliver excellence in services and technology."

About iGambit Inc: iGambit (OTCBB: IGMB) is a fully reporting publicly-held
company. We are a company focused on pursuing specific medical strategies
and objectives. These objectives have included, among others, the
acquisition of medical technology companies with strong growth potential
easily recognized in the public arena. We believe that the back-ground of
our management and of our Board of Directors in the technology markets is a
valuable resource that makes us a desirable business partner. We expect to
work to assume an active role in the development and growth of the new
company, providing both strategic guidance and operational support. The
management of iGambit believes that it can leverage its collective expertise
to help position the combined company to produce high-margin, recurring and
predictable earnings and generate long-term value for our stockholders. For
more information, please visit www.igambit.com <http://www.igambit.com/>; .
Information on our web-site does not comprise a part of this press release.

Cautionary Note Regarding Forward-Looking Statements

Certain statements in this document and elsewhere by iGambit are
"forward-looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995. Such information includes, without
limitation, the business outlook, assessment of market conditions,
anticipated financial and operating results, strategies, future plans,
contingencies and contemplated transactions of the company. Such
forward-looking statements are not guarantees of future performance and are
subject to known and unknown risks, uncertainties and other factors which
may cause or contribute to actual results of company operations, or the
performance or achievements of the company or industry results, to differ
materially from those expressed, or implied by the forward-looking
statements. In addition to any such risks, uncertainties and other factors
discussed elsewhere herein, risks, uncertainties and other factors that
could cause or contribute to actual results differing materially from those
expressed or implied for the forward-looking statements include, but are not
limited to fluctuations in demand; changes to economic growth in the U.S.
and U.S. government policies and regulations, including, but not limited to
those affecting the medical fertility clinic industry. iGambit undertakes no
obligation to publicly update any forward-looking statements, whether as a
result of new information, future events or otherwise. Actual results,
performance or achievements could differ materially from those anticipated
in such forward-looking statements as a result of certain factors, including
those set forth in iGambit Inc.'s filings with the Securities and Exchange
Commission.

Investor Relations Contacts:

Bill Robertson
604 837 3835